Comparative Pharmacology
Head-to-head clinical analysis: IOPAMIDOL 200 IN PLASTIC CONTAINER versus RENOGRAFIN 60.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IOPAMIDOL 200 IN PLASTIC CONTAINER versus RENOGRAFIN 60.
IOPAMIDOL-200 IN PLASTIC CONTAINER vs RENOGRAFIN-60
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iopamidol is a nonionic, water-soluble iodinated radiographic contrast agent that attenuates X-rays by increasing the density of tissues, thereby enhancing vascular and tissue contrast during imaging procedures.
RENOGRAFIN-60 (diatrizoate meglumine and diatrizoate sodium) is an ionic, high-osmolality, iodinated contrast agent. It enhances radiographic contrast by absorbing X-rays due to the high atomic number of iodine. It distributes into the intravascular space and is excreted primarily by the kidneys via glomerular filtration without significant tubular reabsorption or secretion.
Intravascular administration: 1-2 mL/kg (200 mg I/mL) intravenously, up to a maximum of 150 mL per diagnostic procedure. Intraarterial administration: varies by procedure; typical 5-60 mL per injection.
Intravenous: 50-100 mL of a 60% solution as a single dose for CT or angiography. Intra-arterial: 5-50 mL depending on vessel size. Maximum total dose: 3 mL/kg.
None Documented
None Documented
Terminal elimination half-life approximately 2 hours (range 1.5-2.5 hours) in patients with normal renal function; prolonged in renal impairment.
Terminal elimination half-life: 1-2 hours in normal renal function. Prolonged in renal impairment: up to 50 hours. Clinically significant for timing of contrast imaging and risk of contrast-induced nephropathy.
Primarily renal (99% unchanged in urine within 24 hours). Biliary/fecal excretion <1%.
Renal: 95-100% (glomerular filtration, no tubular reabsorption). Biliary/Fecal: negligible.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent